DemeRx has secured a significant $1.7 million grant from the NIH to propel its innovative drug DMX-1001, aimed at treating alcohol use disorder. This funding not only underscores the potential impact of neuroplastogens in addiction therapy but also positions DemeRx to advance its clinical development efforts.
MIAMI–(BUSINESS WIRE)–DemeRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming addiction therapeutics, today announced it was awarded a $1.7 million Small Business Innovation Research (SBIR) Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) at the National Institutes of Health (NIH). This funding will help advance DemeRx’s promising neuroplastogen drug candidate, DMX-1001 (noribogaine), through the necessary IND-enabling studies and toward Pha
Source: Original Press Release
